A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors (NCT06238479)
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors
π©Ί Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase 1a (dose-escalation, dose-optimization) and phase 1b (dose-expansion). The study will last up to approximately 4 years. Eligible patients will have the option to continue taking study drug after the study is complete.
Who can join: Review the eligibility criteria below.
Location: AdventHealth Orlando β Orlando, Florida
Age range: 18 Years
π§ͺ Interventions in This Study
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- AdventHealth Orlando β Orlando, Florida
- Emory University β Atlanta, Georgia
- Massachusetts General Hospital β Boston, Massachusetts
- Washington University School of Medicine β St Louis, Missouri
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island β Mineola, New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health β New York, New York
- Memorial Sloan Kettering Cancer Center β New York, New York
- UT Southwestern Medical Center β Dallas, Texas
- South Texas Accelerated Research Therapeutics (START) β San Antonio, Texas
- Austin Health β Heidelberg,
- Icon Cancer Centre Kurralta Park β Kurralta Park,
- Institut Jules Bordet β Anderlecht,
- Peking University First Hospital β Beijing,
- Hunan Cancer Hospital β Changsha,
- Shanghai East Hospital β Shanghai,
- Centre Oscar Lambret β Lille,
- Centre Leon Berard β Lyon,
- Institut Paoli-Calmettes β Marseille,
- CHU Strasbourg-Hautepierre β Strasbourg,
- Gustave Roussy β Villejuif,
- National Cancer Center Hospital β ChΕ«Εku,
- National Cancer Center Hospital East β Kashiwa,
- The Cancer Institute Hospital of JFCR β KΕtΕ City,
- Kyoto University Hospital β Kyoto,
- Hospital Universitari Vall d'Hebron β Barcelona,
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS β Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) β Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) β Los Angeles, California
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors β Anchorage, Alaska
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors β El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.